Levels of proposed biomarker neurofilament light chain (NfL) are associated with therapeutic effects of disease-modifying treatments (DMTs) in relapsing-remitting multiple sclerosis (RRMS) patients, according to a real-world study.
Study findings also revealed that treatment with either Lemtrada (alemtuzumab, marketed by Sanofi Genzyme), Gilenya (fingolimod, marketed by Novartis), Tecfidera (dimethyl fumarate, marketed by Biogen), or Tysabri (natalizumab, marketed by Biogen) reduced NfL levels to a greater extent than Aubagio (teriflunomide, marketed by Sanofi Genzyme).
The research, “Plasma neurofilament light levels segregate treatment effects: results from the IMSE studies with multiple disease modulatory drugs,” was presented at the 34th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which took place Oct. 10-12 in Berlin.
Fredrik Piehl, MD, PhD, from the Karolinska Institutet in Sweden, presented the data.
Recent evidence has shown that plasma levels of NfL are associated with disease activity in RRMS patients, and are reduced in those starting a DMT. However, comparisons among multiple DMTs in real-world populations are still lacking.
Aiming to address this, the study — funded by Novartis, Sanofi Genzyme, and Biogen — measured NfL in plasma samples from patients starting DMT treatment in the Swedish observational Immunomodulation and Multiple Sclerosis Epidemiology (IMSE) study.
The samples were collected at the start of treatment and at roughly one year (between nine and 15 months) into DMT treatment from RRMS patients, of whom 152 were on Aubagio, 278 on Gilenya, 339 on Tecfidera, 287 on Tysabri, and 89 on Lemtrada. A total of 1,026 controls were used to calculate age-adjusted NfL values.
NfL levels were determined using the Single Molecule Array (Simoa) NF-light Advantage kit.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?